Extending the time window for Tenecteplase by Effective RecanalizatioN of bAsilar artery occLusion in patients with POSTerior circulation stroke (POST ETERNAL)
This important study, called POST ETERNAL, is looking into new ways to treat a very serious type of stroke where a clot blocks a major artery at the back of the brain (basilar artery occlusion). It's a 'Phase III' trial, meaning it's comparing a new treatment strategy to current care. Researchers want to see if a clot-busting medicine called Tenecteplase can be given later than usual after the stroke starts, while still safely and effectively dissolving the clot. The main goal is to find out if this approach can significantly reduce long-term disability or even prevent death, helping more people recover well three months after their stroke.
At a glance
What is this study about?
This study, known as POST ETERNAL, focuses on a specific and severe type of stroke called an "acute ischaemic stroke due to basilar artery occlusion." In simple terms, this means a blood clot has blocked an important artery at the back of your brain (the basilar artery), which can lead to very serious problems or even be life-threatening.
The main aim of this research is to see if a clot-dissolving medicine called Tenecteplase (also known by brand names like Metalyse) can be used effectively even if more time has passed since the stroke began. Currently, clot-busting treatments have a strict time limit to be effective. Doctors want to find out if extending this 'time window' could help more patients recover better, meaning they have less or no disability after their stroke. The study is comparing different clot-busting medicines, including Tenecteplase and Actilyse, to see which is most effective and safe when given at different times.
Researchers will closely monitor how patients recover, particularly looking at their level of independence and disability three months after treatment. They'll use a standard scale called the Modified Rankin Scale (mRS) to assess this. The overall hope is to improve the chances of a good recovery for people who experience this severe type of stroke, potentially by making effective treatment available to more patients.
Key takeaways
- This study is for a serious type of stroke affecting the back of the brain.
- It's testing if a clot-busting medicine (Tenecteplase) can work safely when given later than usual.
- The main goal is to improve recovery and reduce long-term disability.
- Participants will receive study medication and have follow-up assessments for up to a year.
- All adults aged 18+ with this specific stroke-type are potentially eligible.
Who may be eligible?
This study is looking for adult participants, meaning anyone aged 18 years or older, regardless of their sex. To be considered, you would need to have recently experienced an acute ischaemic stroke caused by a blockage in the basilar artery (that crucial blood vessel at the back of the brain).
There might be other specific health requirements or conditions that would mean you can or cannot join the study. These are put in place to ensure the safety of participants and the accuracy of the study results. For example, some pre-existing medical conditions or medications might affect whether you can safely receive the study treatments.
If you think you might be eligible or are interested in learning more, it's really important to talk to your doctor or the research team. They can explain all the detailed criteria and help determine if this study is right for you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Have you recently had a stroke caused by a blood clot in your basilar artery?
- Are you willing and able to attend follow-up appointments for up to 12 months?
- Are you able to provide your consent (agreement) to take part?
What does participation involve?
If you take part in this study, you would receive one of the study medications (either Tenecteplase or Actilyse), which are given as an injection or through a drip into your arm. Doctors will closely monitor your condition during and after this treatment.
Throughout the study, there will be several assessments. Initially, these will be frequent, including checks of your neurological function and scans. You will also have follow-up visits or assessments at 3 months and then again at 12 months. These follow-ups will check your recovery, overall health, and quality of life.
The total duration of your participation in the study, including all follow-up assessments, would be about 12 months. This allows researchers to see the long-term effects of the treatments.
Potential risks and benefits
Locations (1)
- —UnverifiedFrance
Common questions
What is a 'basilar artery occlusion'?
It means a blood clot has blocked a major artery at the back of your brain, which is a serious type of stroke.
What is Tenecteplase?
It's a strong medicine used to dissolve blood clots, often called a 'clot-buster'.
Why are doctors interested in 'extending the time window'?
Current clot-busting treatments have a strict time limit. Researchers want to see if giving Tenecteplase later could still be safe and help more people recover better from stroke.
What does 'disability' refer to in this study?
It refers to how well a person can carry out daily activities and live independently after a stroke, measured on a scale from no symptoms to severe disability or death.
What is the 'Modified Rankin Scale (mRS)'?
It's a commonly used scale that doctors use to measure how much disability someone has after a stroke, ranging from 0 (no symptoms) to 6 (death).
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.